Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Long-Term Deferred Tax (2020 - 2025)

China Pharma Holdings' Long-Term Deferred Tax history spans 10 years, with the latest figure at $22.9 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax rose 5.53% year-over-year to $22.9 million; the TTM value through Dec 2025 reached $22.9 million, up 5.53%, while the annual FY2025 figure was $22.9 million, 5.53% up from the prior year.
  • Long-Term Deferred Tax reached $22.9 million in Q4 2025 per CPHI's latest filing, up from $22.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $24.0 million in Q4 2021 to a low of $21.5 million in Q4 2023.
  • Average Long-Term Deferred Tax over 5 years is $22.4 million, with a median of $22.0 million recorded in 2022.
  • Peak YoY movement for Long-Term Deferred Tax: dropped 13.32% in 2021, then increased 5.53% in 2025.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $24.0 million in 2021, then fell by 8.33% to $22.0 million in 2022, then dropped by 2.07% to $21.5 million in 2023, then rose by 0.78% to $21.7 million in 2024, then rose by 5.53% to $22.9 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Long-Term Deferred Tax are $22.9 million (Q4 2025), $22.7 million (Q3 2025), and $22.1 million (Q2 2025).